 |
|
|
| |
High SVR 12 rates with grazoprevir/elbasvir ± ribavirin
for 12-16 weeks guided by genotypic resistance testing among HIV/HCV coinfected MSM
in the Swiss HCVree Trial
|
| |
| |
Reported by Jules Levin
16th European AIDS Conference, October 25-27, 2017. Milan
Dominique L. Braun1,2, Benjamin Hampel1,2, Roger Kouyos1,
Jürg Böni2, Markus Flepp3, Marcel Stöckle4, Anna Conen5,
Charles Béguelin6, Dunja Nicca7, Patrick Schmid8,
Julie Delaloye9, Mathieu Rougemont10, Enos
Bernasconi11, Huldrych F. Günthard1,Jan Fehr1,
and the Swiss HIV Cohort Study
|
| |
|
|
|
|
|
